Becton Dickinson & Co (NYSE:BDX) is a constituent of the 161 company Health Care Equipment & Supplies GICS industry group, which is part of the 782 company GICS Health Care sector. The market value of BDX is $50.1 billion which falls in the top 10% of its industry group. Portfolio Grader's current ranking for BDX puts it 17 among the 161 companies in this industry group, giving it a well above-average position; in the top decile of the sector with a ranking of 46 among the 782 companies in the sector, and number 268 in the nearly 5,000 company Portfolio Grader universe.

Becton Dickinson & Co (NYSE:BDX) is ranked as a Strong Buy using Louis Navellier's approach to investing and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BDX has had from Portfolio Grader for the last month.

Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using Louis Navellier's investing methodology and his Portfolio Grader stock evaluator. This represents no change from the previous week and is the same ranking BCR has had from Portfolio Grader for 3 months.

Becton Dickinson & Co (NYSE:BDX) is one of the 781 companies in the GICS Health Care sector, and a member of the 161 company Health Care Equipment & Supplies GICS industry group within this sector. The market value of BDX is $51.6 billion which places it in the top decile in its industry group. Currently, the stock's Portfolio Grader ranking places it 18 among the 161 companies in this industry group, placing it among the leaders; in the top decile of the sector with a ranking of 55 among the 781 companies in the sector, and number 301 in the nearly 5,000 company Portfolio Grader universe.

CR Bard Inc (NYSE:BCR) is a $24.3 billion in market value constituent of the Health Care Equipment & Supplies GICS industry group where the stock's Portfolio Grader ranking places it 22 among the 161 companies in this industry group, placing it among the leaders. BCR is ranked among the sector leaders with a ranking of 64 among the 781 companies in the sector and number 364 in the 5000 company Portfolio Grader company universe.

Becton Dickinson & Co (NYSE:BDX) is ranked as a Strong Buy using Louis Navellier's methods for investing and his Portfolio Grader stock evaluator. BDX has recently seen its Portfolio Grader rating upgraded from a Buy to a Strong Buy.

Currently, CR Bard Inc (NYSE:BCR) has a Strong Buy using the system of Louis Navellier for investing and his Portfolio Grader stock evaluator. The current Portfolio Grader recommendation on the shares has been in place for 3 months.

The current recommendation of Strong Buy for Becton Dickinson & Co (NYSE:BDX) is the result of using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. The shares have been upgraded from a Buy to a Strong Buy in the last week.

Portfolio Grader currently ranks CR Bard Inc (NYSE:BCR) a Strong Buy. The methods for investing incorporated in this analytical tool developed by Louis Navellier evaluates and ranks nearly 5,000 stocks each week from a fundamental and quantitative perspective. BCR has maintained this ranking for 3 months.

Becton Dickinson & Co (NYSE:BDX) is classified as a component of the 164 company Health Care Equipment & Supplies GICS industry group, which is part of the 785 company GICS Health Care sector. The market value of BDX is $51.1 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader score places it 14 among the 164 companies in this industry group, positioning it among the leaders; among the sector leaders with a ranking of 34 among the 785 companies in the sector, and number 255 in the nearly 5,000 company Portfolio Grader universe.